白细胞介素1β与白细胞介素1受体拮抗剂在慢性牙周炎中的作用
摘要
<正>慢性牙周炎(chronicperiodontitis, CP)是一种侵犯牙周支持组织的慢性炎症性破坏性疾病,是一种针对细菌感染的宿主免疫应答~([1])。牙菌斑生物膜是牙周病发病的始动因子,细胞因子介导的宿主免疫反应在牙周组织的破坏和发展中发挥着重要的作用。在众多细胞因子中,尤以白细胞介素1与CP的发生发展关
引文
[1] Hong KW, Shin MS, Ahn YB, et al. KimGenomewide association study on chronic periodontitis in Korean population:results from the Yangpyeong health cohort[J]. J Clin Periodontol, 2015,42(8):703-710.
[2]董文亮,田雯,张敬,等.IL-1B和IL-6启动子区基因多态性与宁夏地区回、汉族人群慢性牙周炎的相关性研究[J].牙体牙髓牙周病学杂志,2018,28(7):378-383,417.
[3]黄海霞,兰玉燕,张昊,等.慢性牙周炎患者种植修复后种植体牙周指数及龈沟液炎性因子水平的变化研究[J].国际口腔医学杂志,2018,45(4):396-402.
[4]Boukortt KN, Saidi-Ouahrani N, Boukerzaza B, et al. Association analysis of the IL-1,gene cluster polymorphisms with aggressive and chronic periodontitis in the Algerian population[J]. Arch 0-ral Biol,2015,60(10):1463-1470.
[5]Mazurek-Mochol M,Dembowska E, Malinowski D, et al. IL-1βrs1143634 and rs16944 polymorphisms in patients with periodontal disease[J]. Arch Oral Biol,2019(98):47-51.
[6] Sakalauskiene J,Giedrimiene D,Gleiznys D,et al. Peripheral Blood Leukocytes Interleukin-1 Beta(IL-1β)Cytokine Hyper-Reactivity in Chronic Periodontitis[J]. Med Sci Monit, 2016, 22(12):4323-4329.
[7]赵或卓,张华.围绝经期妇女慢性牙周炎与骨质疏松的相关性分析[J].中国医刊,2017,52(06):61-63.
[8]Gomes FI,Aragao MG, Barbosa FC,et al. Inflammatory Cytokines Interleukin-1βand Tumour Necrosis Factor-α-Novel Biomarkers for the Detection of Periodontal Diseases:a Literature Review[J]. Oral Maxillofac Res,2016, 7(2):e2.
[9] Boukortt K N, Saidi-Ouahrani N, Boukerzaza B,et al. Association analysis of the IL-1,gene cluster polymorphisms with aggressive and chronic periodontitis in the Algerian population[J]. Arch Oral Biol,2015,60(10):1463-1470.
[10] Auerkari E, Suhartono A, Djamal N,et al. CRP and IL-1B gene polymorphisms and CRP in blood in periodontal disease[J]. Open Dent J,2013(7):88-93.
[11]Ribeiro A, Mangeney M, Bernard I,et al. IL-1βand IL-6 modulate apolipoprotein E gene expression in rat hepatocyte primary culture[J]. Mediators Inflamm,1992,1(5):329-333.
[12] Huang XC, He Y, Zhuang J,et al. Mycophenolic acid synergizing with lipopolysaccharide to induce interleukin-1 p release via activation of caspase-1[J]. Chin Med,2018,131(13):1533-1540.
[13] MacKenzie A, Wilson HL,Kiss-Toth E,et al. Rapid secretion of interleukin-1βby microvesicle shedding[J]. Immunity, 2001,15(5):825-835.
[14] Andrei C,Margiocco P,Poggi A,et al. Phospholipases C and A2 control lysosome-mediated IL-1βsecretion:implications for inflammatory processes[J]. Proc Natl Acad Sci USA, 2004,101(26):9745-9750.
[15] Brough D,Rothwell NJ. Caspase-1-dependent processing of pro-interleukin-1βis cytosolic and precedes cell death[J]. Cell Sci, 2007,120(5):772-781.
[16] Gicquel T,Robert S,Loyer P,et al. IL-1βproduction is dependent on the activation of purinergic receptors and NLRP3 pathway in human macrophages[J]. FASEB,2015,29(10):4162-4173.
[17] Cheng R, Liu W, Zhang R, et al. Porphyromonas gingivalis-Derived Lipopolysaccharide Combines Hypoxia to Induce Caspase-1 Activation in Periodontitis[J]. Front Cell Infect Microbiol,2017,14(7):474.
[18] Weber A, Wasiliew P, Kracht M. Interleukin-1(IL-1)pathway[J].Sci Signal,2010,3(105):cml.
[19] Pereira SA, Melo A, Resende E, et al. Antagonistic effect of IL1variants in periodontitis and external apical root resorption:Evidence from a literature review[J]. Arch Oral Biol, 2018, 95(11):195-201.
[20] Nakamura I,Jimi E. Regulation of osteoclast differentiation and function by Interleukin-1[J]. Vitam Horm,2006,(74):357-370.
[21] Dinarello CA. The interleukin-1 family:10years of discovery[J].FASEB,1994,8(15):1314-1325.
[22] Mizutani H, Ishihara Y, Izawa A, et al. Lipopolysaccharide of Aggregatibacter actinomycetemcomitans up-regulates inflammatory cytokines,prostaglandin E synthesis and osteoclast formation in interleukin-1 receptor antagonist-deficient mice[J]. Periodontal Res,2013,48(6):748-756.
[23] Alves De Souza C, Queiroz Alves De Souza A, Queiroz Alves De Souza MDS,et al. A link between osteomyelitis and IL1RN and IL1B polymorphisms—a study in patients from Northeast Brazil[J]. Acta Orthop,2017,88(5):556-561.
[24] Kayar NA, Alptekin NO, Erdal ME, et al. Interleukin-1 receptor antagonist gene polymorphism, adverse pregnancy outcome and periodontitis in Turkish women[J]. Arch Oral Biol,2015,60(12):1777-1783.
[25] Mesa F,Lanza E,García L,et al. Polymorphism IL-1RN rs419598reduces the susceptibility to generalized periodontitis in a population of European descent[J]. PLoS One,2017,12(10):e0186366.
[26] G(u|¨)nther S, Deredge D, Bowers AL,et al. IL-1 family cytokines use distinct molecular mechanisms to signal through their shared coreceptor[J]. Immunity,2017,47(3):510-523.
[27] Tan Q, Huang Q, Ma YL,et al. Potential roles of IL-1 subfamily members in glycolysis in disease[J]. Cytokine Growth Factor Rev,2018,12(44):18-27.
[28] Mesa F,Lanza E,Garcia L,et al. Polymorphism IL-1RN rs419598reduces the susceptibility to generalized periodontitis in a population of European descent[J]. PLoS One,2017,12(10):e0186366.
[29] Izawa A, Ishihara Y, Mizutani H,et al. Inflammatory bone loss in experimental periodontitis induced by Aggregatibacter actinomycetemcomitans in interleukin-1 receptor antagonist knockout mice[J]. Infect Immun, 2014, 82(5):1904-1913.
[30] Kirisawa R, Fukuda T, Yamanaka H. Enzymatic amplification and expression of bovine interleukin-1 receptor antagonist cDNA[J].Vet Immunol Immunopathol,1998,62(3):197-208.
[31] Ishihara Y, Nishihara T, Kuroyanagi T, et al. Gingival crevicular interleukin-1 and interleukin-1 receptor antagonist levels in periodontally healthy and diseased sites[J]. Periodontal Res, 1997,32(6):524-529.
[32] Jimi E,Nakamura I,Duong LT,et al. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells[J].Exp Cell Res,1999,247(1):84-93.
[33] Gilowski L,Wiench R,Plocica I,et al. Amount of interleukin-1βand interleukin-1 receptor antagonist in periodontitis and healthy patients[J]. Arch Oral Biol,2014,59(7):729-734.
[34] Arend WP,Welgus HG,Thompson RC,et al. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist[J].J Clin Invest, 1990,85(5):1694-1967.
[35] Voronov E, Apte RN. Targeting the Tumor Microenvironment by Intervention in Interleukin-1 Biolog[J]. Curr Pharm Des,2017,23(32):4893-4905.
[36] van de Loo FA, van den Berg WB. Lessons from animal models,including studies on interleukin-4, interleukin-10, and interleukin-1 receptor antagonist as potential disease modulators[J]. Rheum Dis Clin North Am,2002,28(1):127-149.
[37] Nixon AJ,Grol MW,Lang HM,et al. Disease-modifying osteoarthritis treatment with interleukin-1 receptor antagonist gene therapy in small and large animal models[J]. Arthritis Rheumatol,2018,70(11):1757-1768.
[2]董文亮,田雯,张敬,等.IL-1B和IL-6启动子区基因多态性与宁夏地区回、汉族人群慢性牙周炎的相关性研究[J].牙体牙髓牙周病学杂志,2018,28(7):378-383,417.
[3]黄海霞,兰玉燕,张昊,等.慢性牙周炎患者种植修复后种植体牙周指数及龈沟液炎性因子水平的变化研究[J].国际口腔医学杂志,2018,45(4):396-402.
[4]Boukortt KN, Saidi-Ouahrani N, Boukerzaza B, et al. Association analysis of the IL-1,gene cluster polymorphisms with aggressive and chronic periodontitis in the Algerian population[J]. Arch 0-ral Biol,2015,60(10):1463-1470.
[5]Mazurek-Mochol M,Dembowska E, Malinowski D, et al. IL-1βrs1143634 and rs16944 polymorphisms in patients with periodontal disease[J]. Arch Oral Biol,2019(98):47-51.
[6] Sakalauskiene J,Giedrimiene D,Gleiznys D,et al. Peripheral Blood Leukocytes Interleukin-1 Beta(IL-1β)Cytokine Hyper-Reactivity in Chronic Periodontitis[J]. Med Sci Monit, 2016, 22(12):4323-4329.
[7]赵或卓,张华.围绝经期妇女慢性牙周炎与骨质疏松的相关性分析[J].中国医刊,2017,52(06):61-63.
[8]Gomes FI,Aragao MG, Barbosa FC,et al. Inflammatory Cytokines Interleukin-1βand Tumour Necrosis Factor-α-Novel Biomarkers for the Detection of Periodontal Diseases:a Literature Review[J]. Oral Maxillofac Res,2016, 7(2):e2.
[9] Boukortt K N, Saidi-Ouahrani N, Boukerzaza B,et al. Association analysis of the IL-1,gene cluster polymorphisms with aggressive and chronic periodontitis in the Algerian population[J]. Arch Oral Biol,2015,60(10):1463-1470.
[10] Auerkari E, Suhartono A, Djamal N,et al. CRP and IL-1B gene polymorphisms and CRP in blood in periodontal disease[J]. Open Dent J,2013(7):88-93.
[11]Ribeiro A, Mangeney M, Bernard I,et al. IL-1βand IL-6 modulate apolipoprotein E gene expression in rat hepatocyte primary culture[J]. Mediators Inflamm,1992,1(5):329-333.
[12] Huang XC, He Y, Zhuang J,et al. Mycophenolic acid synergizing with lipopolysaccharide to induce interleukin-1 p release via activation of caspase-1[J]. Chin Med,2018,131(13):1533-1540.
[13] MacKenzie A, Wilson HL,Kiss-Toth E,et al. Rapid secretion of interleukin-1βby microvesicle shedding[J]. Immunity, 2001,15(5):825-835.
[14] Andrei C,Margiocco P,Poggi A,et al. Phospholipases C and A2 control lysosome-mediated IL-1βsecretion:implications for inflammatory processes[J]. Proc Natl Acad Sci USA, 2004,101(26):9745-9750.
[15] Brough D,Rothwell NJ. Caspase-1-dependent processing of pro-interleukin-1βis cytosolic and precedes cell death[J]. Cell Sci, 2007,120(5):772-781.
[16] Gicquel T,Robert S,Loyer P,et al. IL-1βproduction is dependent on the activation of purinergic receptors and NLRP3 pathway in human macrophages[J]. FASEB,2015,29(10):4162-4173.
[17] Cheng R, Liu W, Zhang R, et al. Porphyromonas gingivalis-Derived Lipopolysaccharide Combines Hypoxia to Induce Caspase-1 Activation in Periodontitis[J]. Front Cell Infect Microbiol,2017,14(7):474.
[18] Weber A, Wasiliew P, Kracht M. Interleukin-1(IL-1)pathway[J].Sci Signal,2010,3(105):cml.
[19] Pereira SA, Melo A, Resende E, et al. Antagonistic effect of IL1variants in periodontitis and external apical root resorption:Evidence from a literature review[J]. Arch Oral Biol, 2018, 95(11):195-201.
[20] Nakamura I,Jimi E. Regulation of osteoclast differentiation and function by Interleukin-1[J]. Vitam Horm,2006,(74):357-370.
[21] Dinarello CA. The interleukin-1 family:10years of discovery[J].FASEB,1994,8(15):1314-1325.
[22] Mizutani H, Ishihara Y, Izawa A, et al. Lipopolysaccharide of Aggregatibacter actinomycetemcomitans up-regulates inflammatory cytokines,prostaglandin E synthesis and osteoclast formation in interleukin-1 receptor antagonist-deficient mice[J]. Periodontal Res,2013,48(6):748-756.
[23] Alves De Souza C, Queiroz Alves De Souza A, Queiroz Alves De Souza MDS,et al. A link between osteomyelitis and IL1RN and IL1B polymorphisms—a study in patients from Northeast Brazil[J]. Acta Orthop,2017,88(5):556-561.
[24] Kayar NA, Alptekin NO, Erdal ME, et al. Interleukin-1 receptor antagonist gene polymorphism, adverse pregnancy outcome and periodontitis in Turkish women[J]. Arch Oral Biol,2015,60(12):1777-1783.
[25] Mesa F,Lanza E,García L,et al. Polymorphism IL-1RN rs419598reduces the susceptibility to generalized periodontitis in a population of European descent[J]. PLoS One,2017,12(10):e0186366.
[26] G(u|¨)nther S, Deredge D, Bowers AL,et al. IL-1 family cytokines use distinct molecular mechanisms to signal through their shared coreceptor[J]. Immunity,2017,47(3):510-523.
[27] Tan Q, Huang Q, Ma YL,et al. Potential roles of IL-1 subfamily members in glycolysis in disease[J]. Cytokine Growth Factor Rev,2018,12(44):18-27.
[28] Mesa F,Lanza E,Garcia L,et al. Polymorphism IL-1RN rs419598reduces the susceptibility to generalized periodontitis in a population of European descent[J]. PLoS One,2017,12(10):e0186366.
[29] Izawa A, Ishihara Y, Mizutani H,et al. Inflammatory bone loss in experimental periodontitis induced by Aggregatibacter actinomycetemcomitans in interleukin-1 receptor antagonist knockout mice[J]. Infect Immun, 2014, 82(5):1904-1913.
[30] Kirisawa R, Fukuda T, Yamanaka H. Enzymatic amplification and expression of bovine interleukin-1 receptor antagonist cDNA[J].Vet Immunol Immunopathol,1998,62(3):197-208.
[31] Ishihara Y, Nishihara T, Kuroyanagi T, et al. Gingival crevicular interleukin-1 and interleukin-1 receptor antagonist levels in periodontally healthy and diseased sites[J]. Periodontal Res, 1997,32(6):524-529.
[32] Jimi E,Nakamura I,Duong LT,et al. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells[J].Exp Cell Res,1999,247(1):84-93.
[33] Gilowski L,Wiench R,Plocica I,et al. Amount of interleukin-1βand interleukin-1 receptor antagonist in periodontitis and healthy patients[J]. Arch Oral Biol,2014,59(7):729-734.
[34] Arend WP,Welgus HG,Thompson RC,et al. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist[J].J Clin Invest, 1990,85(5):1694-1967.
[35] Voronov E, Apte RN. Targeting the Tumor Microenvironment by Intervention in Interleukin-1 Biolog[J]. Curr Pharm Des,2017,23(32):4893-4905.
[36] van de Loo FA, van den Berg WB. Lessons from animal models,including studies on interleukin-4, interleukin-10, and interleukin-1 receptor antagonist as potential disease modulators[J]. Rheum Dis Clin North Am,2002,28(1):127-149.
[37] Nixon AJ,Grol MW,Lang HM,et al. Disease-modifying osteoarthritis treatment with interleukin-1 receptor antagonist gene therapy in small and large animal models[J]. Arthritis Rheumatol,2018,70(11):1757-1768.